Momentum builds for drug research software firm Instem
Instem (INS:AIM) released strong first half revenue growth of 11% to £11.7m, for the period ended 30 June 2019, giving the shares a 2% boost to 382.6p.The Staffordshire-based software solutions provider to the life sciences...
23 September 2019